F17464 in Acute Schizophrenia Trial

Summary

The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design: double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre study.

Timeline

Start

2014-06

Primary completion

2015-12

Completion

2015-12

Drugs

Indications